Every year brings its own distinct changes. For the life sciences industry, 2022 was marked by challenges such as the ongoing influence of the pandemic, a turbulent economy and a...
Read More
LISTEN TO THE PODCAST In this episode, we sit down with scientist and entrepreneur Daniel J. Mandell, Ph.D. Daniel is the Chief Executive Officer, Co-Founder, and Director of GRO Biosciences,...
Read More
After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr. Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.
Therapeutic proteins are used to treat a wide variety of diseases, from cancer and heart disease to cystic fibrosis and diabetes. These proteins currently are produced using microbial fermentation in...
Read More
GRO Biosciences tackles ‘Holy Grail’ challenges, using non-standard amino acids to expand the amino acid palette Last month, GRObio completed a $25-million Series A financing co-led by Leaps by Bayer...
Read More
The startup engineers microbes to make proteins that incorporate non-standard amino acids Humans, like most living organisms, rely on just 20 amino acids to make the thousands of different proteins...
Read More
Harvard University spinout GRO Biosciences has technology offering the potential for protein therapies that are safer and more effective than currently available biologic drugs. The startup's research is now backed...
Read More
George Church discusses the biotechnology underpinning GRO Biosciences Inc., which could provide a workaround for some well-known problems in protein therapeutics. The startup just hauled in millions to tackle those problems.
Six years ago, Daniel Mandell appeared on NPR to talk about an invention out of Jurassic Park. As Crichton and Goldblum fans recall, International Genetic Technologies, Inc.’s contingency plan to...
Read More
Beyond Meat (BYND) was one of last year’s hottest stocks. Shares of the plant-based meat company exploded 859% during its first three months out of the gate.
